ERVW-1 and infection: Over the last decade, evidence has accumulated from passive immunization studies to suggest that a vaccine that elicits broadly neutralizing antibodies (bNAbs) to the HIV envelope glycoprotein (Env), prior to infection, can provide protective immunity against HIV (3–11).